MONTREAL, October 2nd, 2023 – Replicor Inc. announced the presentation of clinical data from the compassionate use of REP 2139-Mg in its first Canadian patient with HBV / HDV / HIV co-infection at the 2023 Special Topic Conference on HBV held by the Canadian Association for the Study of the Liver, September 29 – October 1 2023 in Calgary, Canada (see here).
Compassionate use of REP 2139-Mg is underway in Replicor’s first Canadian patient and the first patient with HIV co-infection, under the supervision or Dr. Sebastien Poulin (Clinique L’Agora, Montreal, Canada). This patient had progressed to advanced liver disease (cirrhosis) and had failed previous therapy with pegylated interferon. The data presented (see here) shows that addition of REP 2139-Mg to existing antiviral therapy led to clearance of HDV RNA after 17 weeks of REP 2139-Mg therapy with good tolerability and no adverse events. Importantly control of HIV infection was not compromised in this patient in the presence of REP 2139-Mg.
Dr. Andrew Vaillant, CSO of Replicor commented, “We are pleased to see the successful expansion of compassionate of REP 2139-Mg not only in Canada but also in patients with co-infection with HIV. This initial safety and efficacy data will support the expansion of REP 2139-Mg use in HBV and HBV / HDV infected patients who also have HIV infection.”
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV infection. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.